polatuzumab vedotin,Obinutuzumab,rituximab,Lenalidomide
Roche
['lymsm']
congress | #ash22 catherine s. diefenbach presents data from the phase ib/ii study of pola-g-len in pts with r/r #fl. the best overall response rate was 91%, with a best cr rate of 72%. after a median follow-up of 43.3 months, median pfs was not reached. #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm